NO20002773L - Substituerte imidazolderivater med agonist-liknende virkning pÕ <alfa> 2B eller 2B/2C adrenerge reseptorer - Google Patents

Substituerte imidazolderivater med agonist-liknende virkning pÕ <alfa> 2B eller 2B/2C adrenerge reseptorer

Info

Publication number
NO20002773L
NO20002773L NO20002773A NO20002773A NO20002773L NO 20002773 L NO20002773 L NO 20002773L NO 20002773 A NO20002773 A NO 20002773A NO 20002773 A NO20002773 A NO 20002773A NO 20002773 L NO20002773 L NO 20002773L
Authority
NO
Norway
Prior art keywords
alfa
agonist
effect
adrenergic receptors
imidazole derivatives
Prior art date
Application number
NO20002773A
Other languages
English (en)
Other versions
NO317292B1 (no
NO20002773D0 (no
Inventor
Ken Chow
Daniel W Gil
James A Burke
Dale A Harcourt
Michael E Garst
Larry A Wheeler
Stephen A Munk
Original Assignee
Allergan Sales Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales Inc filed Critical Allergan Sales Inc
Publication of NO20002773D0 publication Critical patent/NO20002773D0/no
Publication of NO20002773L publication Critical patent/NO20002773L/no
Publication of NO317292B1 publication Critical patent/NO317292B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/28—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20002773A 1997-12-04 2000-05-30 Substituerte imidazolderivater med agonist-liknende virkning pa <alfa> 2B eller 2B/2C adrenerge reseptorer NO317292B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98534797A 1997-12-04 1997-12-04
PCT/US1998/025669 WO1999028300A1 (en) 1997-12-04 1998-12-03 Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors

Publications (3)

Publication Number Publication Date
NO20002773D0 NO20002773D0 (no) 2000-05-30
NO20002773L true NO20002773L (no) 2000-08-02
NO317292B1 NO317292B1 (no) 2004-10-04

Family

ID=25531403

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20002773A NO317292B1 (no) 1997-12-04 2000-05-30 Substituerte imidazolderivater med agonist-liknende virkning pa <alfa> 2B eller 2B/2C adrenerge reseptorer
NO20035490A NO20035490D0 (no) 1997-12-04 2003-12-10 Substituerte imidazolderivater med agonist-liknende virkning på alfa 2B eller 2B/2C adrenerge reseptorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20035490A NO20035490D0 (no) 1997-12-04 2003-12-10 Substituerte imidazolderivater med agonist-liknende virkning på alfa 2B eller 2B/2C adrenerge reseptorer

Country Status (22)

Country Link
EP (2) EP1413576A3 (no)
JP (3) JP4783502B2 (no)
KR (1) KR100544787B1 (no)
CN (1) CN1284066A (no)
AR (1) AR017807A1 (no)
AT (1) ATE266643T1 (no)
AU (1) AU744798B2 (no)
BR (1) BR9813381A (no)
CA (1) CA2312334A1 (no)
DE (1) DE69823868T2 (no)
DK (1) DK1036065T3 (no)
ES (1) ES2216339T3 (no)
HU (1) HUP0004557A3 (no)
IL (2) IL136388A0 (no)
NO (2) NO317292B1 (no)
NZ (1) NZ504667A (no)
PL (1) PL341009A1 (no)
PT (1) PT1036065E (no)
RU (1) RU2235092C2 (no)
SK (1) SK8542000A3 (no)
TW (1) TW577878B (no)
WO (1) WO1999028300A1 (no)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002254265B2 (en) * 1997-12-04 2008-05-15 Allergan, Inc. Imidiazole derivatives and their use as agonists selective at alpha 2B or 2B/2C adrenergic receptors
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
PL341009A1 (en) * 1997-12-04 2001-03-12 Allergan Sales Substitute derivatives of imidazole exhibiting agonist-like activity in respect to adrenergic alpha 2b or 2b/2c receptors
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
FI20000073A0 (fi) * 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
US6388090B2 (en) 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6593324B2 (en) 2000-03-01 2003-07-15 Orion Corporation Dervatives of quinoline as alpha-2 antagonists
JP2006036636A (ja) * 2000-11-22 2006-02-09 Nippon Shinyaku Co Ltd 消化管機能障害治療剤及びスクリーニング方法
FR2825926A1 (fr) * 2001-06-14 2002-12-20 Sod Conseils Rech Applic Derives d'imidazoles modulant les canaux sodiques
HRP20041026A2 (en) 2002-04-03 2005-06-30 Orion Corporation Polycyclic compounds as potent alpha2-adrenoceptor antagonists
WO2003088992A1 (fr) * 2002-04-22 2003-10-30 Takeda Chemical Industries, Ltd. Nouvelle methode de criblage
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7276522B2 (en) 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7323485B2 (en) 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7358269B2 (en) 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
JP4724421B2 (ja) * 2002-10-08 2011-07-13 アラーガン、インコーポレイテッド 神経変性を処置するためのα２Ｂまたは２Ｂ／２Ｃアドレナリン受容体アゴニスト
CA2501348A1 (en) * 2002-10-08 2004-04-22 Allergan, Inc. Treatment of dementia and parkinson's disease
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
AU2005300030B2 (en) 2004-09-20 2012-01-12 Janssen Pharmaceutica N.V. Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
US7338973B2 (en) 2004-09-20 2008-03-04 Janssen Pharmaceutica N.V. Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
WO2006036497A2 (en) * 2004-09-24 2006-04-06 Allergan, Inc. 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
WO2006036480A1 (en) * 2004-09-24 2006-04-06 Allergan, Inc. 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
WO2006036507A1 (en) 2004-09-24 2006-04-06 Allergan, Inc. 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
CA2582071A1 (en) * 2004-09-28 2006-04-06 Allergan, Inc. Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
US7390829B2 (en) 2005-06-29 2008-06-24 Allergan, Inc. Alpha-2 adrenergic agonists
WO2007024949A2 (en) 2005-08-25 2007-03-01 Schering Corporation Alpha2c adrenoreceptor agonists
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
US7592362B2 (en) 2006-01-19 2009-09-22 Pfizer Limited Substituted imidazoles
RU2008130448A (ru) 2006-01-27 2010-03-10 Ф. Хоффманн-Ля Рош Аг (Ch) Применение производных 4-имидазола для расстройств цнс
CN101426788A (zh) * 2006-04-20 2009-05-06 詹森药业有限公司 用作药物的取代吡嗪酮衍生物
WO2007135131A1 (en) * 2006-05-22 2007-11-29 Janssen Pharmaceutica N.V. Substituted pyrazinone derivatives for use as a medicine
RU2009112496A (ru) 2006-10-19 2010-11-27 Ф. Хоффманн-Ля Рош Аг (Ch) Аминометил-4-имидазолы
CA2668454A1 (en) 2006-11-02 2008-05-08 F. Hoffmann-La Roche Ag Substituted 2-imidazoles
JP2010510184A (ja) * 2006-11-16 2010-04-02 エフ．ホフマン−ラ ロシュ アーゲー 置換４−イミダゾール類
CN101190218B (zh) * 2006-11-20 2010-12-22 四川科瑞德制药有限公司 替扎尼定及其衍生物在制备抗焦虑症药物中的用途
CA2672617A1 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2-imidazoles as ligands for trace amine associated receptors (taar)
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
US8013169B2 (en) 2007-01-12 2011-09-06 Allergan, Inc Naphthylmethylimidizoles as therapeutic agents
WO2008088937A1 (en) * 2007-01-12 2008-07-24 Allergan, Inc. Quinolynylmethylimidizoles as therapeutic agents
WO2008088936A1 (en) * 2007-01-12 2008-07-24 Allergan, Inc. Quinolynylmethylimidizoles as therapeutic agents
CN101600700B (zh) 2007-02-02 2013-08-21 弗·哈夫曼-拉罗切有限公司 作为taar1配体用于cns病症的新的2-氨基噁唑啉
WO2008100459A1 (en) 2007-02-13 2008-08-21 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
EP2398776A1 (en) 2007-02-13 2011-12-28 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
BRPI0807961A2 (pt) 2007-02-13 2017-05-16 Pharmacopeia Llc agonista de alfa2c adrenorreceptor funcionalmente seletivos.
KR101222412B1 (ko) 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
ES2390323T3 (es) * 2007-05-23 2012-11-08 Allergan, Inc. Compuestos terapéuticos de ((fenil)imidazolil)metilquinolinilo
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
CN101687812A (zh) 2007-07-02 2010-03-31 弗·哈夫曼-拉罗切有限公司 对痕量胺相关受体(taar)具有良好亲和性的2-咪唑啉化合物
CA2691704A1 (en) 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
AU2008276278A1 (en) * 2007-07-17 2009-01-22 Allergan, Inc. Methods for treating anxiety
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
CA2694362A1 (en) 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
JP5341084B2 (ja) 2007-08-03 2013-11-13 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体
WO2009020578A1 (en) * 2007-08-06 2009-02-12 Schering Corporation Alpha2c adrenoreceptor agonists
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
AU2009205539B2 (en) * 2008-01-18 2013-12-05 Allergan.Inc Substitued-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
WO2009105504A2 (en) 2008-02-21 2009-08-27 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
BRPI0912604A2 (pt) * 2008-05-13 2019-09-10 Allergan Inc quinolinilmetilimidazóis como agentes terapêuticos
DE102008001932A1 (de) 2008-05-21 2009-11-26 Bayer Cropscience Ag Substiuierte Spiroisoxazoline
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US8324213B2 (en) 2008-10-07 2012-12-04 Merck Sharp & Dohme Corp. Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
CA2818144C (en) * 2010-11-16 2020-09-22 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
AU2012340806B2 (en) 2011-11-21 2017-10-19 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
AR090557A1 (es) * 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
CN108713019B (zh) 2016-03-17 2021-06-15 豪夫迈·罗氏有限公司 具有作为taar的激动剂的活性的5-乙基-4-甲基-吡唑-3-甲酰胺衍生物
CN110240542B (zh) * 2019-06-24 2020-05-12 牡丹江医学院 一种选择性β1-肾上腺素受体抑制剂及其在制备心血管疾病药物中的用途
EP4419519A4 (en) * 2021-10-20 2025-09-10 Assembly Biosciences Inc PROCESS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85747A1 (fr) * 1985-01-28 1986-08-04 Continental Pharma Derives d'imidazole leur preparation et utilisation ainsi que les compositions pharmaceutiques contenant des derives
FI864570A0 (fi) * 1986-11-11 1986-11-11 Farmos Oy Terapeutiskt anvaendbar foerening.
US4882343A (en) * 1987-08-28 1989-11-21 G. D. Searle & Co. Biarylalkylimidazole derivatives as anti-depressants
JPH01242571A (ja) * 1988-03-22 1989-09-27 Mitsui Petrochem Ind Ltd イミダゾール誘導体の製造方法
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
DE69212164T2 (de) * 1991-12-18 1996-12-05 Schering Corp., Kenilworth, N.J. Imidolylalkyl-derivate substituiert mit einem stickstoffenthaltende-6 gliedrigen ring
AU5118493A (en) * 1992-10-06 1994-04-26 Tokyo Tanabe Company Limited Aromatase inhibitor
JPH11505224A (ja) * 1995-05-12 1999-05-18 アラーガン 心臓血管系副作用を伴わないα▲下２▼アドレナリン作動剤として有用なアリール−イミダゾリンおよびアリール−イミダゾール
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US5621113A (en) * 1996-03-28 1997-04-15 Ortho Pharmaceutical Corporation 4-[(thien-2-yl)methyl]-imidazole analgesics
US5750720A (en) * 1996-03-28 1998-05-12 Ortho Pharmaceutical Corporation 4- (thien-3-yl)methyl!-imidazole analgesics
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
PL341009A1 (en) * 1997-12-04 2001-03-12 Allergan Sales Substitute derivatives of imidazole exhibiting agonist-like activity in respect to adrenergic alpha 2b or 2b/2c receptors

Also Published As

Publication number Publication date
RU2235092C2 (ru) 2004-08-27
WO1999028300A1 (en) 1999-06-10
NO20035490D0 (no) 2003-12-10
ES2216339T3 (es) 2004-10-16
DE69823868T2 (de) 2005-04-21
IL136388A (en) 2006-12-31
AR017807A1 (es) 2001-10-24
KR20010032776A (ko) 2001-04-25
JP2014012724A (ja) 2014-01-23
NO317292B1 (no) 2004-10-04
CA2312334A1 (en) 1999-06-10
SK8542000A3 (en) 2001-03-12
NZ504667A (en) 2003-03-28
EP1036065A1 (en) 2000-09-20
JP2010209111A (ja) 2010-09-24
EP1036065B1 (en) 2004-05-12
EP1413576A2 (en) 2004-04-28
IL136388A0 (en) 2001-06-14
KR100544787B1 (ko) 2006-01-23
JP2001524542A (ja) 2001-12-04
JP4783502B2 (ja) 2011-09-28
TW577878B (en) 2004-03-01
AU1802599A (en) 1999-06-16
EP1413576A3 (en) 2004-09-01
HUP0004557A3 (en) 2002-03-28
BR9813381A (pt) 2000-10-03
NO20002773D0 (no) 2000-05-30
HUP0004557A2 (hu) 2002-02-28
PL341009A1 (en) 2001-03-12
AU744798B2 (en) 2002-03-07
CN1284066A (zh) 2001-02-14
DE69823868D1 (de) 2004-06-17
PT1036065E (pt) 2004-09-30
ATE266643T1 (de) 2004-05-15
DK1036065T3 (da) 2004-08-30

Similar Documents

Publication Publication Date Title
NO20002773D0 (no) Substituerte imidazolderivater med agonist-liknende virkning pÕ &lt;alfa&gt; 2B eller 2B/2C adrenerge reseptorer
NO20004912D0 (no) Forbindelser med innvirkning pÕ muskarinreseptorer
ITMI991964A0 (it) Derivati benzimidazolonici aventi affinita&#39; mista per i recettori di s erotonina e dopamina
ATE246700T1 (de) Benzimidazolderivate
NO963776D0 (no) (4,4-Difluorbut-3-enyltio)-substituerte heterosykliske eller karbocykliske ringforbindelser med disinfiserende virkning
NO20006220D0 (no) &lt;beta&gt;2-adrenergistiske reseptoragonister
NO333123B1 (no) Arrangement for marin forankring
HUP0104390A3 (en) Imidazole derivatives as selective agonists at alpha 2b or 2b/2c adrenergic receptors
PT1189916E (pt) N-pirazole agonistas do receptor a2a
DE69903953D1 (de) 2-substituierte-1-piperidyl-benzimidazolverbindungen als orl1 rezeptor agonisten
NO20001983L (no) Amidderivater eller salter derav
NO20004845L (no) Marin konstruksjon
NO993736D0 (no) Termisk bildedannende forretningsformular med omrÕde som er maskert eller gjort ufölsomt
EP1023061A4 (en) SOMATOSTATINAGONISTE
BR9206237A (pt) Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1.
DE69921124D1 (de) Imidazolderivate und ihre verwendung als somatostatin rezeptorliganden
PT1131291E (pt) Antagonistas iii do receptor 4-aroil-piperidin-ccr-3
DE60029034D1 (de) Flugverwaltungssystem
NO914263D0 (no) Indol- og benzimidazolsubstituerte imidazol- og benzimidazol-derivater
NO20013013D0 (no) &lt;alfa&gt;v&lt;beta&gt;6-integrininhibitorer
PT1122243E (pt) Novos imidazoles com actividades anti-inflamatoria
EP0994900A4 (en) semaphorin
DE60015963D1 (de) Ermüdungserleichterung an der struktur eines luftfahrzeuges
DE69819258D1 (de) Kammerrakelsystem
DK1068198T3 (da) 5-Heteroarylsubstituerede indoler